Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms

Objective: This study was planned to compare the effects of gabapentin and isoflavones in menopausal vasomotor symptoms. Materials and Methods: This prospective comparative study was conducted on 100 patients with complaints of hot flashes, divided into two groups of 50 each. Group I received 900 mg...

Full description

Saved in:
Bibliographic Details
Main Authors: Savita Rani Singhal (Author), Wansalan Kuru Shullai (Author)
Format: Book
Published: Wolters Kluwer Medknow Publications, 2016-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_4a6a815f76e942f78c8068f9b9fad0e3
042 |a dc 
100 1 0 |a Savita Rani Singhal  |e author 
700 1 0 |a Wansalan Kuru Shullai  |e author 
245 0 0 |a Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms 
260 |b Wolters Kluwer Medknow Publications,   |c 2016-01-01T00:00:00Z. 
500 |a 0976-7800 
500 |a 0976-7819 
500 |a 10.4103/0976-7800.191017 
520 |a Objective: This study was planned to compare the effects of gabapentin and isoflavones in menopausal vasomotor symptoms. Materials and Methods: This prospective comparative study was conducted on 100 patients with complaints of hot flashes, divided into two groups of 50 each. Group I received 900 mg of gabapentin and Group II received 60 mg of isoflavones daily for 3 months. The patients were interviewed to calculate hot flash, global and depression scores and were rescored after 2, 4, 8, and 12 weeks. The primary outcome measure was a change in the hot flash score from baseline. The secondary outcome was an improvement in sleep, depression, and lipid profile. Data were analyzed using Chi-square test and Student's t-test. Results: Both groups showed significant improvement in hot flash score at the end of 12 weeks (82% Group I, 74% Group II; P = 0.076). Statistically significant difference was seen at 12 weeks in sleep quality in favor of gabapentin (P = 0.011) and in depression in favor of isoflavones (0.026). Isoflavone had significant improvement in cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides profiles after 12 weeks (P < 0.001, 0.009, 0.024 and <0.001, respectively) as compared to gabapentin. Conclusion: Isoflavone and gabapentin are equally effective in the treatment of hot flashes; however, isoflavones have better response in patients who have associated with complaints of depression and gabapentin is better who have associated sleep disturbance. 
546 |a EN 
690 |a Gabapentin 
690 |a hot flashes 
690 |a isoflavone 
690 |a menopause 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
690 |a Geriatrics 
690 |a RC952-954.6 
655 7 |a article  |2 local 
786 0 |n Journal of Mid-Life Health, Vol 7, Iss 3, Pp 132-139 (2016) 
787 0 |n http://www.jmidlifehealth.org/article.asp?issn=0976-7800;year=2016;volume=7;issue=3;spage=132;epage=139;aulast=Singhal 
787 0 |n https://doaj.org/toc/0976-7800 
787 0 |n https://doaj.org/toc/0976-7819 
856 4 1 |u https://doaj.org/article/4a6a815f76e942f78c8068f9b9fad0e3  |z Connect to this object online.